<DOC>
	<DOCNO>NCT01865812</DOCNO>
	<brief_summary>The purpose study determine obeticholic acid ( OCA ) effect cholesterol level blood patient PBC .</brief_summary>
	<brief_title>Phase 2 Study Effects Obeticholic Acid ( OCA ) Lipoprotein Metabolism Subjects With Primary Biliary Cirrhosis</brief_title>
	<detailed_description>This phase 2 , open-label , multicenter study evaluate effect OCA lipoprotein metabolism subject PBC ; particular , OCA 's effect high density lipoprotein ( HDL ) cholesterol . Nuclear magnetic resonance ( NMR ) spectroscopy utilized quantify change lipoprotein particle sizes concentration . Components reverse cholesterol transport also assess .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Liver Cirrhosis</mesh_term>
	<mesh_term>Liver Cirrhosis , Biliary</mesh_term>
	<mesh_term>Chenodeoxycholic Acid</mesh_term>
	<criteria>1 . Definite probable primary biliary cirrhosis ( PBC ) diagnosis demonstrate presence ≥ 2 follow 3 diagnostic factor : History elevate alkaline phosphatase ( ALP ) level least 6 month A positive antimicrobial antibody ( AMA ) titer , AMA negative low titer ( &lt; 1:80 ) , PBC specific antibody Liver biopsy consistent PBC 2 . Age ≥ 18 year 3 . Taking UDCA least 12 month ( stable dose ≥ 3 month ) prior Day 0 unable tolerate UDCA ( UDCA ≥ 3 month prior Day 0 ) 4 . Contraception : Female subject must postmenopausal , surgically sterile , premenopausal , prepare use ≥ 1 effective ( ≤ 1 % failure rate ) method contraception trial least 30 day last dose Investigational Product . 5 . Must provide write informed consent agree comply trial protocol . 1 . Subjects decompensated PBC ( determine Investigator ) 2 . Severe pruritus systemic treatment pruritus ( e.g . treatment bile acid sequestrants rifampicin ) within 2 month Day 0 3 . History presence significant liver diseases include : Active chronic Hepatitis B C virus ( HBV , HCV ) infection Primary sclerosing cholangitis ( PSC ) Alcoholic liver disease Definite autoimmune liver disease overlap hepatitis Nonalcoholic steatohepatitis ( NASH ) NOTE : Subjects Gilbert 's disease history hepatitis B currently antigen negative seroconverted consider exclusionary 4 . Uncontrolled diabetes uncontrolled unstable medical condition may interfere trial result 5 . Administration follow medication specify : Prohibited 28 day prior Day 0 : bile acid sequestrants ( BAS ) include cholestyramine , colesevelam , colestipol omega3 fatty acid contain dietary supplement Prohibited 3 month prior Day 0 throughout trial participation : serumlipid modify agent include 3hydroxy3methylglutarylcoenzyme A ( HMG CoA ) reductase inhibitor , fenofibrate fibrates , nicotinic acid derivative , ezetimibe , Vitamin E ( standard dietary supplement ) Prohibited 6 month prior Day 0 throughout trial participation : azathioprine , colchicine , cyclosporine , methotrexate , mycophenolate mofetil , pentoxifylline ; budesonide systemic corticosteroid ; potentially hepatotoxic drug ( include αmethyldopa , sodium valproic acid , isoniazide , nitrofurantoin ) Prohibited 12 month prior Day 0 throughout trial participation : antibody immunotherapy direct interleukin cytokine chemokines 6 . Planned change diet exercise habit participation trial 7 . Presence history clinically significant cardiac arrhythmia may prohibit subject participate trial 8 . If female : know pregnancy , positive urine pregnancy test ( confirm positive serum pregnancy test ) , lactate 9 . Recent ( 3 month prior day 0 ) participation another trial involve OCA participation another investigational trial ( 30 day prior Day 0 ) trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>